ArticleBMC infectious diseases2024
Nontuberculous mycobacterial pulmonary disease (NTM PD) incidence trends in the United States, 2010-2019.
Article in BMC infectious diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Non-tuberculous mycobacterial infections among pulmonary tuberculosis suspected and confirmed patients in Ethiopia - A systematic review and meta analyses.BMC infectious diseases · 2025Pooled it
- Randomized study of the efficacy, safety, and pharmacokinetics of SPR720 for the treatment of Mycobacterium avium complex pulmonary disease.Scientific reports · 2026Trial
- Gut-lung axis and microbiome alterations in mycobacterial infections: from pathogenesis to therapeutic potential.Gut microbes · 2026Review
- Inflammatory bowel disease and risk of non-tuberculous mycobacterial pulmonary disease: a nationwide retrospective cohort study in Korea.Journal of thoracic disease · 2026Article
- Evaluation of the deeplex Myc-TB-targeted next-generation sequencing assay for mycobacterial identification and drug resistance detection.Journal of clinical microbiology · 2026Article
- Incidence trends of nontuberculous mycobacterial pulmonary infections in Australia, Cambodia, Japan, Thailand, and the United States.medRxiv : the preprint server for health sciences · 2026Article
- Mycobacterial cell division arrest and smooth-to-rough envelope transition using CRISPRi-mediated genetic repression systems.FEBS open bio · 2026Article
- Nontuberculous Mycobacteria Pulmonary Disease Prevalence, New York City, 2012 to 2020.CHEST pulmonary · 2026Article
- Zoonotic Nontuberculous Mycobacteria: Transmission Pathways, Laboratory Diagnosis, Detection Methodologies, and One Health Priorities.Infectious diseases & clinical microbiology · 2026Review
- Review
- Pulmonary nontuberculous mycobacterial infection is associated with urinary molybdenum concentrations in a bronchiectasis cohort.Environmental epidemiology (Philadelphia, Pa.) · 2026Article
- Efficacies of Sequenced Monotherapies of Mycobacterium avium Lung Infection in Mouse.The Journal of infectious diseases · 2026Article
- The risk of NTM pulmonary infection associated with trace metal exposure from public distribution system water in the United States.Journal of exposure science & environmental epidemiology · 2026Article
- Molecular Techniques for MTBC and NTM Differentiation: Diagnostic Accuracy of STANDARD™ M10 MTB/NTM and Potential Applications.Diagnostics (Basel, Switzerland) · 2026Article
- Why a Mycobacterium Avium Infected Patient Showed a Positive Xpert MTB/RIF Result?Clinical case reports · 2026Article
- A cross-environment comparison of nontuberculous mycobacterial diversity.Applied and environmental microbiology · 2026Article
- Molecular epidemiology of non-tuberculous mycobacteria in clinical samples from Jiangxi Province, 2021-2023.BMC microbiology · 2026Article
- Distinguishing nontuberculous mycobacterial lung disease from pulmonary tuberculosis using radiomics machine learning models from CT images.Frontiers in medicine · 2026Article
- Review of the Canadian Nontuberculous Mycobacterial Disease Landscape-Challenges and Opportunities.Tropical medicine and infectious disease · 2025Review
- Epidemiology and Drug Susceptibility of Nontuberculous Mycobacteria in the Province of Pavia (Northern Italy): An Overview.Microorganisms · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNontuberculous mycobacteria (NTM) are ubiquitous environmental bacteria that cause chronic lung disease. Rates of NTM pulmonary disease (NTM PD) have increased over the last several decades, yet national estimates in the United States (US) have not been assessed since 2015.
methodsWe used a nationally representative population of Medicare beneficiaries aged ≥ 65 years to assess rates of NTM PD in a high-risk population from 2010 to 2019. Poisson generalized linear models were used to assess the annual percent change in incidence in the overall population and among key demographic groups such as sex, geography, and race/ethnicity. We evaluated the relative prevalence of various comorbid conditions previously found to be associated with NTM PD.
resultsWe identified 59,724 cases of incident NTM PD from 2010 to 2019 from an annual mean population of 29,687,097 beneficiaries, with an average annual incidence of 20.1 per 100,000 population. NTM PD incidence was overall highest in the South and among women, Asian individuals, and persons aged ≥ 80 years relative to other studied demographic groups. The annual percent change in NTM PD incidence was highest in the Northeast, at 6.5%, and Midwest, at 5.9%, and among women, at 6.5%. Several comorbid conditions were highly associated with concurrent NTM diagnosis, including allergic bronchopulmonary aspergillosis, bronchiectasis, and cystic fibrosis.
conclusionsHere we provide current estimates of NTM PD incidence and prevalence and describe increasing trends in the US from 2010 to 2019. Our study suggests a need for improved healthcare planning to handle an increased future caseload, as well as improved diagnostics and therapeutics to better detect and treat NTM PD in populations aged ≥ 65 years.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.